InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Danziger Asaf, Chairman & CEO. Officer active across 1 companies, notably NovoCure Ltd. Aggregated, 6 reports have been recorded. Total volume traded: €707k. The latest transaction was disclosed on 6 January 2022 — Attribution. Regulator: SEC (Form 4). The full history is free.
Declarations6 total
€1,74931 shares@ €56.40870.0001% mcap0.5% of flow
Ordinary Shares
SEC:0001645113-22-000004·
€1,74931 shares@ €56.40870.0001% mcap0.2% of flow
Ordinary Shares
SEC:0001645113-22-000004:0·
€353,3863,870 shares@ €91.31430.024% mcap95.8% of flow
Ordinary Shares
SEC:0001645113-21-000116·
Ideal exit: 23 Aug 2022 (T+270)
€353,3863,870 shares@ €91.31430.024% mcap47.9% of flow
Ordinary Shares
SEC:0001645113-21-000116:0·
Ideal exit: 23 Aug 2022 (T+270)
€13,684118 shares@ €115.96410.0009% mcap3.7% of flow
Ordinary Shares
SEC:0001645113-21-000084·
€13,684118 shares@ €115.96410.0009% mcap1.9% of flow
Ordinary Shares
SEC:0001645113-21-000084:0·
6 of 6 declarations
About Danziger Asaf
Asaf Danziger serves as Chief Executive Officer of NovoCure Ltd. In this role, he is responsible for the overall direction of the company and the implementation of its strategy. Asaf Danziger oversees all operations and ensures that NovoCure meets its growth objectives. His leadership is essential in guiding the company in the healthcare sector.
